Search

Displaying results 1451 - 1460 of 3735 in total
  1. Drug

    Valsartan

    go.drugbank.com/drugs/DB00177
    ApprovedInvestigational

    Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease … In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function.

    Mixtures: VALSARTAN COMP PU 160/12.5, VALSARTAN COMP PU 160/12.5Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Inhibitors
  2. Drug

    Oxethazaine

    go.drugbank.com/drugs/DB12532
    ApprovedWithdrawn

    Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at low pH

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  3. Drug

    Sodium ferric gluconate complex

    go.drugbank.com/drugs/DB09517
    Approved

    The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 – 440,000 daltons on gel chromatography.

  4. Drug

    Indocyanine green acid form

    go.drugbank.com/drugs/DB09374
    ApprovedInvestigational

    Indocyanine Green for Injection USP has a pH of approximately 6.5 when reconstituted.

  5. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  6. Drug

    PF-06282999

    go.drugbank.com/drugs/DB11683
    Investigational

    Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).

  7. Drug

    PF-06260414

    go.drugbank.com/drugs/DB15221
    Investigational

    PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

  8. Drug

    Rabeprazole

    go.drugbank.com/drugs/DB01129
    ApprovedInvestigational

    Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inducers
  9. Drug

    Ragweed pollen extract

    go.drugbank.com/drugs/DB05368
    ApprovedWithdrawn

    Ragweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. While traditional disease-modifying immunotherapeutics are administered by su...

  10. Drug

    Tenecteplase

    go.drugbank.com/drugs/DB00031
    ApprovedInvestigational

    Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 1...